Novo Nordisk shares pop 5% after Wegovy receives U.S. approval for liver disease

Core Insights - Novo Nordisk's Wegovy obesity drug received accelerated approval from the U.S. FDA to treat metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis [2] - Following the announcement, Novo Nordisk's shares increased by approximately 5% [1][2] Company Developments - The FDA approval is contingent upon the use of Wegovy in conjunction with a reduced calorie diet and increased physical activity [2] - The stock price of Novo Nordisk rose by 5.05% by 9:59 a.m. London time, indicating positive market reaction to the news [2]